Pierre Gravier Sells 2,516 Shares of PTC Therapeutics, Inc. (NASDAQ:PTCT) Stock

PTC Therapeutics, Inc. (NASDAQ:PTCT - Get Free Report) CFO Pierre Gravier sold 2,516 shares of the firm's stock in a transaction on Tuesday, July 15th. The stock was sold at an average price of $49.46, for a total value of $124,441.36. Following the completion of the sale, the chief financial officer directly owned 71,920 shares of the company's stock, valued at approximately $3,557,163.20. This trade represents a 3.38% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

PTC Therapeutics Stock Performance

NASDAQ:PTCT traded down $0.90 during trading hours on Friday, reaching $47.63. The company's stock had a trading volume of 628,561 shares, compared to its average volume of 875,491. The firm has a market capitalization of $3.78 billion, a price-to-earnings ratio of 7.32 and a beta of 0.50. The firm has a 50-day simple moving average of $48.83 and a 200-day simple moving average of $48.48. PTC Therapeutics, Inc. has a 1 year low of $29.02 and a 1 year high of $58.38.

PTC Therapeutics (NASDAQ:PTCT - Get Free Report) last issued its earnings results on Tuesday, May 6th. The biopharmaceutical company reported $10.04 EPS for the quarter, topping the consensus estimate of $0.85 by $9.19. The company had revenue of $1.18 billion for the quarter, compared to the consensus estimate of $437.16 million. PTC Therapeutics had a net margin of 33.56% and a negative return on equity of 78.56%. The firm's revenue for the quarter was down 9.6% on a year-over-year basis. During the same period in the previous year, the firm earned ($1.20) earnings per share. Equities analysts anticipate that PTC Therapeutics, Inc. will post -4.52 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research analysts have recently commented on PTCT shares. Robert W. Baird dropped their price target on shares of PTC Therapeutics from $70.00 to $66.00 and set an "outperform" rating on the stock in a research note on Wednesday, May 7th. Royal Bank Of Canada boosted their price target on PTC Therapeutics from $57.00 to $58.00 and gave the stock an "outperform" rating in a research report on Wednesday, May 7th. JPMorgan Chase & Co. lowered their price objective on PTC Therapeutics from $75.00 to $67.00 and set an "overweight" rating on the stock in a report on Wednesday, May 7th. Citigroup upgraded shares of PTC Therapeutics from a "sell" rating to a "neutral" rating and decreased their price target for the stock from $50.00 to $40.00 in a research report on Wednesday, May 7th. Finally, Cantor Fitzgerald lowered their price target on PTC Therapeutics from $113.00 to $112.00 and set an "overweight" rating on the stock in a research note on Wednesday, May 7th. One research analyst has rated the stock with a sell rating, four have issued a hold rating, ten have issued a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus target price of $65.00.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the company. Vanguard Group Inc. boosted its holdings in PTC Therapeutics by 0.6% in the fourth quarter. Vanguard Group Inc. now owns 9,178,822 shares of the biopharmaceutical company's stock worth $414,332,000 after acquiring an additional 53,688 shares in the last quarter. Wellington Management Group LLP raised its position in shares of PTC Therapeutics by 13.2% in the 1st quarter. Wellington Management Group LLP now owns 5,419,172 shares of the biopharmaceutical company's stock worth $276,161,000 after purchasing an additional 632,049 shares during the last quarter. Toronto Dominion Bank bought a new position in PTC Therapeutics in the 4th quarter worth about $148,363,000. Janus Henderson Group PLC grew its position in PTC Therapeutics by 24.4% during the 4th quarter. Janus Henderson Group PLC now owns 2,325,915 shares of the biopharmaceutical company's stock valued at $105,015,000 after purchasing an additional 455,698 shares during the last quarter. Finally, Driehaus Capital Management LLC increased its stake in PTC Therapeutics by 45.3% during the 1st quarter. Driehaus Capital Management LLC now owns 1,512,645 shares of the biopharmaceutical company's stock valued at $77,084,000 after purchasing an additional 471,586 shares in the last quarter.

PTC Therapeutics Company Profile

PTC Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children.